BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
30 sept. 2019 06h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
25 sept. 2019 09h55 HE
|
Schall Law
LOS ANGELES, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
18 sept. 2019 10h50 HE
|
Schall Law
LOS ANGELES, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
13 sept. 2019 17h06 HE
|
Schall Law
LOS ANGELES, Sept. 13, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BeiGene, Ltd....
BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
11 sept. 2019 16h30 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update
08 sept. 2019 01h01 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
03 sept. 2019 08h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
21 août 2019 16h30 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 21, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Reports Second Quarter 2019 Financial Results
08 août 2019 16h05 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
07 juil. 2019 20h00 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...